Functional and survival effect of bevacizumab and irinotecan administered at recurrence in a cohort of patients with GBM.
E. Tabouret
No relevant relationships to disclose
M. Barrie
No relevant relationships to disclose
C. Boucard
No relevant relationships to disclose
M. Matta
No relevant relationships to disclose
D. Autran
No relevant relationships to disclose
A. Loundou
No relevant relationships to disclose
O. L. Chinot
Consultant or Advisory Role - Roche
Research Funding - Roche